NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, announced today that it will host its RNA Revolution Conference on Wednesday, July 17, 2019 at the 1 Hotel Central Park in New York City.
ROTH’s RNA Revolution Conference will give investors the opportunity to dive deep into scientific discussions about differences between various RNA modalities (mRNA, ASO, siRNA, and RNA-targeted small molecule), the nuances of drug delivery, and how improvements have made these drugs more effective and safer. Yasmeen Rahimi, Ph.D., Co-Head of Biotechnology Research and Senior Research Analyst, will moderate four panel discussions on topics that address how companies are innovating in the main areas of RNA medicine. The panels are “From the Past to the Future: ASOs and Small Molecules,” “Knock Knock, Who’s at the Door? siRNA with Large Market Opportunities” and “Mirror, Mirror on the Wall, Why Would mRNA Deliver it All?”, with a fourth, key panel “A Delivery Revolution Beyond the Liver” that will allow investors to learn the ins and outs of RNA medicine delivery beyond the liver. Also, interact in one-on-one meetings with leading experts who have significant expertise in mRNA and ASO delivery, readthrough from pre-clinical studies to clinical trials, and what makes for a clean and efficacious RNA therapeutic.
ROTH has built a leading Healthcare Investment Banking Group over the last several years and has raised approximately $17+ billion in over 400 Healthcare transactions since 2010.*Past Performance is not indicative of future returns. (Source: ROTH Capital Partners | 06/26/2019)
The event is for institutional clients of ROTH and is by invitation only. For more information, please see www.roth.com/healthcare or contact your ROTH sales representative at (949) 720-5700 or e-mail: firstname.lastname@example.org
Agenda and Events:
7:00AM - 8:00AM | Registration and Morning Coffee
7:45AM - 8:00AM | Introduction by Yasmeen Rahimi, Ph.D.
8:00AM - 5:00PM | Industry Panels (Details Below)
9:00AM - 3:45PM | 1-on-1 / Small Group Meetings (excluding panel times)
12:00PM - 1:00PM | Working Lunch
8:00AM - 9:00AM | Panel: From the past, to the future: ASOs and small molecules
12:00PM -1:00PM | Panel: Knock, knock, who's at the door? siRNA, with large market opportunities
2:00PM - 3:00PM | Panel: Mirror, mirror on the wall, why would mRNA deliver all?
4:00PM - 5:00PM | Panel: A delivery revolution beyond the liver
1 Hotel Central Park
1414 Avenue of the Americas, New York, NY, 10019
The following participating companies are confirmed as of the date of this release:
Akcea Therapeutics, Inc. (AKCA)
Arbutus Biopharma Corporation (ABUS)
Arcturus Therapeutics Holdings, Inc. (ARCT)
Arrakis Therapeutics (PRIVATE)
Arrowhead Pharmaceuticals, Inc. (ARWR)
Dicerna Pharmaceuticals, Inc. (DRNA)
Medicines Company (MDCO)
Moderna, Inc. (MRNA)
NeuBase Therapeutics, Inc. (PRIVATE)
Event sponsors include Business Wire and Lowenstein Sandler.
About Roth Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.